دورية أكاديمية
The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
| العنوان: | The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab |
|---|---|
| المؤلفون: | Carvalho, B, Lopes, JM, Silva, R, Peixoto, J, Leitão, D, Soares, P, Fernandes, AC, Linhares, P, Vaz, R, Lima, J |
| المساهمون: | Instituto de Investigação e Inovação em Saúde |
| بيانات النشر: | Nature Publishing Group |
| سنة النشر: | 2021 |
| المجموعة: | Repositório Aberto da Universidade do Porto |
| مصطلحات موضوعية: | Adult, Aged, Bevacizumab / administration & dosage, Disease-Free Survival, Drug Resistance, Neoplasm / drug effects, Female, Gene Expression Regulation, Neoplastic / drug effects, Glioblastoma / blood supply, Glioblastoma / drug therapy, Glioblastoma / metabolism, Glioblastoma / mortality, Humans, Male, Middle Aged, Proto-Oncogene Proteins c-met / biosynthesis, Retrospective Studies, Survival Rate, Vascular Endothelial Growth Factor Receptor-2 / biosynthesis |
| الوصف: | Dismal prognosis of glioblastoma (GBM) prompts for the identification of response predictors and therapeutic resistance mechanisms of current therapies. The authors investigated the impact of c-Met, HGF, VEGFR2 expression and microvessel density (MVD) in GBM patients submitted to second-line chemotherapy with bevacizumab. Immunohistochemical expression of c-Met, HGF, VEGFR2, and MVD was assessed in tumor specimens of GBM patients treated with bevacizumab, after progression under temozolomide. Survival analysis was evaluated according to the expression of the aforementioned biomarkers. c-Met overexpression was associated with a time-to-progression (TTP) after bevacizumab of 3 months (95% CI, 1.5–4.5) compared with a TTP of 7 months (95% CI, 4.6–9.4) in patients with low or no expression of c-Met (p = 0.05). VEGFR2 expression was associated with a TTP after bevacizumab of 3 months (95% CI, 1.8–4.2) compared with a TTP of 7 months (95% CI, 5.7–8.3) in patients with no tumoral expression of VEGFR2 (p = 0.009). Concomitant c-Met/VEGFR2 overexpression was associated with worse overall survival (13 months) compared with concomitant c-Met/VEGFR2 negative expression (19 months; p = 0.025). Our data support the hypothesis that c-Met and VEGFR2 overexpression have a role in the development of glioblastoma early resistance and might predict poorer responses to anti-angiogenic therapies. ; This work was financed by FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT-Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274). Additional funding by the European Regional Development Fund (ERDF), COMPETE2020 and Portuguese national funds via FCT, under project POCI-01-0145-FEDER-016390: CANCEL STEM and the project ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2045-2322 |
| العلاقة: | info:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC%2FMED-ONC%2F31438%2F2017/PT; Scientific Reports, vol.11(1):6067; https://www.nature.com/articles/s41598-021-85385-1Test; https://hdl.handle.net/10216/152451Test |
| DOI: | 10.1038/s41598-021-85385-1 |
| الإتاحة: | https://doi.org/10.1038/s41598-021-85385-1Test https://hdl.handle.net/10216/152451Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.884D7B7B |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20452322 |
|---|---|
| DOI: | 10.1038/s41598-021-85385-1 |